Biofrontera AG (FRA:B8FK) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 28, 2026)


FRA:B8FK Biofrontera AG FRA:B8FK
56 GF Score
Price €2.21
GF Value €2.29
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Biofrontera AG Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Biofrontera AG's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:B8FK vs ZTS, UTHR, VTRS: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biofrontera AG Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Biofrontera AG's Margin of Safety % (DCF Earnings Based) falls into.


FRA:B8FK
56GF Score
Biofrontera AG FRA:B8FK
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biofrontera AG (FRA:B8FK) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera AG stock appears to be undervalued. The current stock price of €2.21 is trading 3.5% below its estimated GF Value™ of €2.29. GuruFocus considers Biofrontera AG to be Fairly Valued.

Key valuation signals for FRA:B8FK:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €2.29 vs. price of €2.21 (3.5% below fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the FRA:B8FK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofrontera AG Business Description

Other Exchanges 0DOL:UKB8FK:Germany
Address Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
56GF Score

Get the complete analysis for FRA:B8FK

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.21
Price
€2.29
GF Value